Barclays PLC Talaris Therapeutics, Inc. Transaction History

Barclays PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 07, 2023	BUY	$2.68 - $3.22 $28,533 - $34,283	10,647 Added 151.04%	17,696 $50,000
Q2 2023 Aug 03, 2023	SELL	$1.78 - $3.2 $20,845 - $37,475	-11,711 Reduced 62.43%	7,049 $21,000
Q1 2023 May 04, 2023	BUY	$1.09 - $2.09 $6,014 - $11,532	5,518 Added 41.67%	18,760 $35,000
Q4 2022 Feb 13, 2023	BUY	$0.94 - $1.64 $4,902 - $8,552	5,215 Added 64.97%	13,242 $13,000
Q3 2022 Nov 03, 2022	SELL	$2.3 - $5.03 $338 - $739	-147 Reduced 1.8%	8,027 $22,000
Q2 2022 Aug 12, 2022	SELL	$4.51 - $9.85 $15,361 - $33,549	-3,406 Reduced 29.41%	8,174 $37,000
Q1 2022 May 16, 2022	BUY	$6.89 - $16.56 $79,786 - $191,764	11,580 New	11,580 $114,000

75.7K

Ticker TALS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,995,900
Market Cap $109M
Description
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, an...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.